Type 2 diabetes mellitus and obesity – dangerous companions

Czech version

Authors: Zbynek Schroner
Authors‘ workplace: Lekárska fakulta, Univerzita Pavla Jozefa Šafárika v Košiciach
Published in: Diab Obez 2024; 24(1): 36-38
Category:

Overview

Obesity is often associated with high prevalence of type 2 diabetes mellitus. Type 2 diabetes has high occurence in countries with high prevalence of overweight and obesity. These two chronic diseases act as inseparable companions. Their current occurence and tight pathophysiologic connection led to creation of term – diabesity. Weight reduction in patients with type 2 diabetes is possible through several modalities. Basis is intervention of life style, consequently antidiabetics/antiobesitics and last but not least possibility of bariatric metabolic surgery, possibly their mutual combination.

Keywords:

obesity – management – type 2 diabetes mellitus – weight control

Sources

Fábryová Ľ. Diabetes mellitus a obezita (diabezita) : základy manažmentu In: Fábryová Ľ (Ed) et al. Klinická obezitológia. FAMA: Brno 2023. ISBN 978–80–88056–16–4.

NCZI 2023. Činnosť diabetologických ambulancií v Slovenskej republike 2022. Dostupné z WWW: <https://www.nczisk.sk/aktuality/pages>.

Chan JM, Rimm EB, Colditz et al. Obesity, fat distribution and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994; 17(9): 961–969. Dostupné z DOI: <http://dx.doi.org/10.2337/diacare.17.9.961>.

Colditz GA, Willett WC, Rotnizky A et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Inter Med 1995; 122(7): 481–486. Dostupné z DOI: <http://dx.doi.org/10.7326/0003–4819–122–7-199504010–00001>.

Martinka E, Tkáč I, Mokáň M et al. Odporúčané postupy pre liečbu diabetes mellitus 2. typu – 2023. Forum Diab 2023; 12(2): 93–133.

Boye KS, Ford JH, Thieu VT et al. The association between obesity and the 5-year prevalence of morbidity and mortality among adults with type 2 diabetes. Diabetes Ther 2023; 14(4): 709–721. Dostupné z DOI: <http://dx.doi.org/10.1007/s13300–023–01384–7>.

Lean MEJ, Leslie WS, Barnes AC et.al. Primary care-led weight management for remission of type 2 diabetes (DIRECT): an open -label, cluster-randomised trial. Lancet 2018; 391: 541–551. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(17)33102–1>.

Hammoud R, Drucker D. Beyond the pancreas: constrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol 2023; 19(4): 201–216. Dostupné z DOI: <http://dx.doi.org/10.1038/s41574–022–00783–3>.

Holst JJ, Rosenkilde MM. GIP as a therapeutic target in diabetes and obesity: Insight from incretin co-agonists. J Clin Endocrinol Matab 2020; 105(8): e2710-e2716. Dostupné z DOI: <http://dx.doi.org/10.1210/clinem/dgaa327>.

Nauck MA, D’Alesio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. Cardiovasc Diabetol 2022; 21(1): 169. Dostupné z DOI: <http://dx.doi.org/10.1186/s12933–022–01604–7>.

Fábryová Ľ, Holéczy P (eds) et al. DIABEZITA: Diabetes a obezita – nerozlučné dvojičky. Facta Medica: Brno 2019. ISBN 978–80–88056–09–6.